Physician profile
James Obrien
NPI 1740284553
$514.82
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.56 · 2020: $343 · 2021: $86.38 · 2022: $12.64.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $102.48 | 2020-2021 | |
| Pfizer INC. | $66.05 | 2020 | |
| Amgen INC. | $57.31 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.73 | 2020 | |
| Currax Pharmaceuticals LLC | $37.08 | 2020 | |
| Merck Sharp & Dohme LLC | $34.78 | 2020 | |
| Glaxosmithkline, LLC. | $29.97 | 2019-2021 | |
| Novo Nordisk INC | $27.37 | 2020-2021 | |
| Abbvie INC. | $25.81 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $15.28 | 2020 | |
| Lilly USA, LLC | $14.29 | 2020 | |
| Radius Health, INC. | $13.92 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.38 | 2020 | |
| Horizon Therapeutics Plc | $13.22 | 2019 | |
| Eisai INC. | $13.14 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $13.01 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Obrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.